Sentence: Palbociclib is a selective cyclin-dependent kinase ( CDK ) 4/6 inhibitor used in combination with aromatase inhibitors or fulvestrant for patients with hormone receptor-positive ( HR+ ) human epidermal growth factor receptor 2 (HER2)-negative advanced/metastatic breast cancer ( ABC/MBC ) .
Drug combination annotation:
[{'class': 'POS', 'spans': ['Palbociclib', 'fulvestrant'], 'is_context_needed': True}]